Evaluation of the Prophylactic Antimalarial Activity of a Single Dose of DSM265 in Non-immune Healthy Adult Volunteers by Controlled Human Malaria Infection With PfSPZ Challenge
Phase of Trial: Phase I
Latest Information Update: 19 Jun 2017
Price : $35 *
At a glance
- Drugs DSM 265 (Primary) ; Atovaquone/proguanil
- Indications Malaria
- Focus First in man; Therapeutic Use
- 01 Jun 2017 Results published in The Lancet Infectious Diseases
- 02 Dec 2016 Status changed from active, no longer recruiting to completed.
- 06 Jul 2016 Planned End Date changed from 1 Nov 2016 to 1 Jan 2017.